Raquel Torres

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Xueqian Gong, Lacey M. Litchfield, Yue Webster et al. · Cancer Cell · 2017 · 236 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR

Carlos Díez-Freire, Jorge Vázquez, Maria Fernanda Correa de Adjounian et al. · Physiological Genomics · 2006 · 199 citations

Medicine, Cardiology, Pharmacology +17

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Jian Du, Lei Yan, Raquel Torres et al. · Molecular Cancer Therapeutics · 2019 · 52 citations · Full text

Medicine, Oncology, Pharmacology +15

Alpha-II-Spectrin after Controlled Cortical Impact in the Immature Rat Brain

Jada M. Aikman, Barbara E. O'Steen, X. Silver et al. · Developmental Neuroscience · 2006 · 38 citations

Life Sciences, Neurobiology, Neuroscience +12